Herantis Pharma’s HER-096 Shows Promising Phase 1b Data in Parkinson’s Trial
Event summary
- Herantis Pharma will present Phase 1b trial data for HER-096 at AD/PD 2026 on March 18, 2026.
- The trial met all primary and secondary endpoints, demonstrating safety and tolerability in Parkinson’s patients.
- Biomarker analyses showed HER-096 modulated key Parkinson’s disease pathways, including proteostasis and neuroinflammation.
- HER-096 achieved sufficient cerebrospinal fluid (CSF) concentration to cross the blood-brain barrier.
The big picture
Herantis Pharma’s Phase 1b data for HER-096 represents a critical milestone in the development of disease-modifying therapies for Parkinson’s disease. The positive results align with broader industry efforts to target neuroinflammation and proteostasis, key drivers of neurodegeneration. With plans to advance into Phase 2 trials, Herantis is positioning itself as a contender in a market desperate for treatments that can halt or reverse disease progression.
What we're watching
- Clinical Progression
- Whether HER-096 can replicate these results in a larger Phase 2 proof-of-concept study.
- Regulatory Pathway
- The timeline for regulatory approvals and the potential for accelerated pathways given the unmet need in Parkinson’s disease.
- Competitive Landscape
- How Herantis Pharma positions HER-096 against other emerging therapies targeting neurodegeneration.
Related topics